The FDA adverse-event record for llama

Llama Adverse Event Insights

The FDA Center for Veterinary Medicine database holds 9 adverse event reports for Llama, distributed across 0 distinct breeds currently tracked in the system. Of those reports, 3 involved a death outcome, producing a 33.3% case-fatality rate among reported events, which reflects reporting severity bias rather than true population mortality. These figures are aggregated directly from openFDA's Animal & Veterinary Adverse Events endpoint and update as new voluntary submissions flow through pet owners, veterinarians, and drug manufacturers.

The most frequently reported clinical signs for Llama are Ataxia (3 reports), Death (3 reports), Injection site abscess (2 reports), Lack of efficacy (endoparasite) - roundworm NOS (1 reports), with Ataxia leading the reaction traffic at 3 submissions. On the product side, Ivermectin is the single most-referenced drug with 3 reports, followed by Fenbendazole (2), Moxidectin (1), Amprolium Ion (1). This combination surfaces which therapeutic classes generate the most adverse event chatter for this species, a useful starting point when comparing Llama reporting patterns against other companion animals in the dataset.

Of the 8 Llama reports with a coded outcome, Outcome Unknown accounts for the largest share at 37.5%. Annual submission volume spans 2,010 to 2,025 reports across the 7 years on file, a range that reflects evolving owner awareness, veterinary reporting habits, and new product approvals rather than stable underlying incidence. The breed-level table below breaks these patterns down further, showing how the 0 tracked llama breeds compare on volume, deaths, and average age at report. As with all FDA adverse event data, correlation is the ceiling, causation requires clinical investigation beyond what these aggregates can provide.